Yale University: Schizophrenia trials

The registry lists 53 Schizophrenia studies with Yale University as lead sponsor. 2 are open to participants now and 20 have results posted.

Early Phase 1 2Phase 1 8Phase 2 14Phase 3 8Phase 4 1No phase 24(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Genetic Basis of the Risk and Consequences of Cannabis Exposure in HumansRecruitingNCT06058702Phase 1
• Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) ScanningRecruitingNCT01730781
• Song-making In a Group (SING) R61CompletedNCT05537428Not applicableResults posted
• Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations ResultsTerminatedNCT04548622Not applicableResults posted
• Models of Auditory HallucinationTerminatedNCT04210557Not applicableResults posted
• Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in SchizophreniaTerminatedNCT03132571Phase 2Results posted
• Cannabidiol Treatment in Patients With Early PsychosisCompletedNCT02504151Phase 2Results posted
• Acetylcholine, Tobacco Smoking, Genes and Nicotinic ReceptorsCompletedNCT02008292Not applicableResults posted
• Translational Neuroscience Optimization of GlyT1 InhibitorCompletedNCT01911676Phase 2Results posted
• Naltrexone for Antipsychotic-Induced Weight GainCompletedNCT01866098Not applicableResults posted
• A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in SchizophreniaCompletedNCT01232790Not applicableResults posted
• Pilot Trial of Naltrexone for Obesity in Women With SchizophreniaCompletedNCT00793780Not applicableResults posted
• Randomized, Controlled, Double Blind Trial of Eszopiclone for Insomnia Associated With SchizophreniaCompletedNCT00645944Not applicableResults posted
• Cannabidiol Treatment of Cognitive Dysfunction in SchizophreniaCompletedNCT00588731Phase 2Results posted
• Treatment With Acamprosate in Patients With Schizophrenia and Comorbid AlcoholismCompletedNCT00463346Phase 3Results posted
• Efficacy of Pimozide Augmentation for Clozapine Partial ResponseCompletedNCT00374244Phase 2Results posted
• Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid AlcoholismCompletedNCT00338598Phase 2Results posted
• Specialized Treatment Early in Psychosis (STEP)CompletedNCT00309452Not applicableResults posted
• Transcranial Magnetic Stimulation for "Voices"CompletedNCT00308997Phase 2Results posted
• Glycine vs Placebo for the Schizophrenia ProdromeCompletedNCT00291226Phase 2/3Results posted
• D-Serine Treatment of Negative Symptoms and Cognitive Deficits in SchizophreniaCompletedNCT00237809Phase 3Results posted
• Repetitive Transcranial Magnetic Stimulation for "Voices"CompletedNCT00004980Phase 2Results posted
• Song-making In a Group (SING)CompletedNCT05929352Not applicable
• M1 Schizophrenia PET StudyCompletedNCT05105542Phase 1
• SV2 PET Imaging With [11C]APP311Active, not recruitingNCT03995121
• BXCL501 for Agitation in SchizophreniaCompletedNCT03708315Phase 1
• Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) AntagonismCompletedNCT02675530Phase 1
• Regulation of Arginine-vasopressin (AVP)CompletedNCT02626832Not applicable
• A Pilot Trial of Curcumin Effects on Cognition in SchizophreniaTerminatedNCT02476708Not applicable
• Probing the Cannabinoid System in Individuals With a Family History of PsychosisActive, not recruitingNCT02102113Early Phase 1
• STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.CompletedNCT02069925Not applicable
• Social Cognitive Training for Psychosis: Treatment DevelopmentCompletedNCT01579422Phase 1
• An Open-Label Pilot Trial of Alpha Lipoic Acid (ALA) for Weight Loss in SchizophreniaCompletedNCT01355952Not applicable
• Benefits Management for People With Psychiatric DisabilitiesCompletedNCT01329393Phase 1
• Milestones of Adjustment Post-PsychosisTerminatedNCT01192594Phase 3
• Lifestyle Modification for Weight Loss in SchizophreniaCompletedNCT00990925Not applicable
• Effects of Delta-9-THC and Iomazenil in Healthy HumansCompletedNCT00982982Early Phase 1
• Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy SubjectsCompletedNCT00690170Phase 1
• Ethyl-EPA Treatment of Prodromal PatientsCompletedNCT00634361Phase 2/3
• The Effect of Plasma Osmolality on Brain GlutamateCompletedNCT00611741Phase 1
• Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original StudyCompletedNCT00567281Not applicable
• Galantamine for Cognitive Deficits in SchizophreniaCompletedNCT00463879Phase 2/3
• Effects of Atomoxetine on Cognitive Function in SchizophreniaCompletedNCT00420498Phase 2
• Recovery Guide Intervention for Recurrent Psychiatric HospitalizationCompletedNCT00400166Not applicable
• Treatment of Refractory Schizophrenia With RiluzoleCompletedNCT00375050Not applicable
• Cognitive Training and Enhanced Supported Employment in SchizophreniaCompletedNCT00339170Not applicable
• Enhancing the Prospective Prediction of PsychosisCompletedNCT00291200
• Glycine Treatment of Prodromal SymptomsCompletedNCT00268749Phase 2
• Aripiprazole Treatment of Prodromal PatientsCompletedNCT00237874Phase 2/3
• Effectiveness of Atypical Versus Conventional Antipsychotics in Treating SchizophreniaCompletedNCT00237861Phase 4
• D-Serine for Enhancing Cognitive Retraining for the Treatment of SchizophreniaCompletedNCT00237848Phase 3
• Prevalence of Diabetes Mellitus Among Patients Treated With Atypical and Conventional AntipsychoticsCompletedNCT00224276
• Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory HallucinationsCompletedNCT00042159Not applicable